Back to trials
withdrawn
Not Applicable

NCT00256035

Interleukin-4 (IL-4) as a Marker of Atherosclerosis

Sponsored by Melbourne Health

Summary

In recent years, medical research into the cause and progression of heart disease due to narrowing and blockage of blood vessels to the heart muscle has improved the understanding of ischemic heart disease. It is now accepted that both the development and later progression with sudden blockage of blood vessels are associated with inflammation, although it remains unknown exactly what triggers this inflammatory process. It is possible that new blood tests which measure markers of inflammation in the bloodstream may be useful to help identify patients at risk of heart damage and assess response to treatment. The study plans to assess a new blood test for a known marker of inflammation (IL-4) in patients with heart disease. The hypothesis of this study is that, the cytokine, IL-4, measured by a new assay, is abnormally elevated in the blood of patients with coronary artery disease. Also hypothesized is that the degree of abnormality of blood IL-4, is related to important clinical events in such patients, including severity of disease, acute complications, and treatment.

Eligibility Criteria

Inclusion Criteria: * All patients (either sex and any age) presenting in the settings described will be eligible to participate. Exclusion Criteria: * An unwillingness to participate.

Why you can trust this information
Registry sourcesclinicaltrials_gov
Source last updated4/27/2015
Clintriva indexed9/27/2026, 9:21:09 PM
Registry records1
Relationships needing review0

Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.

Interested in this trial?

Express your interest and we'll connect you with the trial team.

Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.

Quick Facts
Start Date—
Completion—
Enrollment—
Country—

Conditions

Atherosclerosis
Ischemic Heart Disease
View on registry
Clintriva
GDPR Controls Mapped HIPAA Safeguards Mapped NHS DSP Controls Mapped SOC 2 Controls Mapped

© 2026 Clintriva. All rights reserved.